Skip to main content

Advertisement

We’d like to understand how you use our websites in order to improve them. Register your interest.

Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers

Kaposi's sarcoma-associated herpesvirus (KSHV) is linked to three different human cancers: Kaposi's sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). We have previously reported that the PI3K/Akt/mTOR pathway is critical for the survival of KSHV-infected endothelial cells and B cells, and have demonstrated that Rapamycin/Sirolimus, an inhibitor of mTOR, can induce PEL cell death in vitro and in vivo (Sin et al., Blood. 2007. 109(5):2165–73). We have now extended these findings and demonstrate that therapeutic targeting of other members of the PI3K/Akt/mTOR signal transduction pathway can also induce cell death in PEL in vitro and inhibit tumor growth in murine xenograft models. Importantly, some of these novel drug candidates have passed clinical trials for other indications and can therefore be tested for efficacy against KS and AIDS-associated lymphomas.

Author information

Affiliations

Authors

Corresponding author

Correspondence to B Damania.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bhatt, A., Bhende, P. & Damania, B. Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers. Infect Agents Cancer 4, O7 (2009). https://doi.org/10.1186/1750-9378-4-S2-O7

Download citation

Keywords

  • Cell Death
  • Lymphoma
  • Tumor Growth
  • Sarcoma
  • Therapeutic Target